shutterstock-173719850-web
Kutlayev Dmitry / Shutterstock.com
12 December 2014Pharma

Drug makers on brink of $65bn patent cliff, says report

Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
22 October 2026   Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.
Pharma
22 October 2026   Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.
Pharma
20 October 2026   In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.